Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Dennis A. Ausiello, a director of Alnylam Pharmaceuticals, executed multiple equity transactions on 08/14/2025 under a Rule 10b5-1(c) trading plan adopted May 15, 2025. The Form 4 reports exercises of stock options (codes M(1)) for option blocks of 9,000; 5,153; 4,581; 5,228; 4,032; and 3,454 shares at exercise prices ranging from $72.01 to $189.87 per share, each creating corresponding shares of common stock. The filing also shows open-market sales (codes S(1)) of multiple share blocks at weighted-average prices reported in ranges between $430.39 and $443.10 per share. After the reported transactions, the reporting person’s beneficial ownership counts are shown on individual lines (for example, 9,911; 15,064; 19,645; 24,873; 28,905; 32,359; then decreasing after sales to 911). Additionally, 3,500 shares are reported as indirectly owned by a trust for which the reporting person's spouse is trustee. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Ausiello on 08/15/2025.
Alnylam Pharmaceuticals (ALNY) reported a proposed sale under Rule 144 of 31,448 common shares valued at $13,635,538.00 based on the filing. The shares were acquired and are to be sold on 08/14/2025 through UBS Financial Services, Inc. via the exercise of stock options and paid in cash. The filing lists 131,079,015 shares outstanding for the class. The filer reports no shares sold in the past three months. The notice includes the signer’s representation that they are unaware of any undisclosed material adverse information about the issuer.
Alnylam Pharmaceuticals announced significant organizational changes with the combination of its Research and Early Development function and Development function into a single R&D organization. Key leadership appointments include:
- Dr. Pushkal Garg promoted to Executive VP, Chief Research and Development Officer with new compensation package: - Base salary: $825,000 - Annual incentive target: 65% of base salary - Long-term equity incentives to be determined
- Dr. Kevin Fitzgerald (Executive VP, Chief Scientific Officer) receives expanded responsibilities for external innovation with: - Increased annual incentive target to 60% of base salary - One-time restricted stock unit grant valued at $2.5M, vesting over 3 years
This strategic reorganization aims to streamline R&D operations and strengthen the company's innovation capabilities. The changes were approved by the People, Culture and Compensation Committee on June 12, 2025, with formal announcement made on June 18, 2025.